These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 7615355)

  • 1. Expression of tumor-associated 90K-antigen in human breast cancer: no correlation with prognosis and response to first-line therapy with tamoxifen.
    Foekens JA; Klijn JG; Natoli C; van Putten WL; Di Stefano P; Look MP; Portengen H; Iacobelli S
    Int J Cancer; 1995 Apr; 64(2):130-4. PubMed ID: 7615355
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Urokinase-type plasminogen activator and its inhibitor PAI-1: predictors of poor response to tamoxifen therapy in recurrent breast cancer.
    Foekens JA; Look MP; Peters HA; van Putten WL; Portengen H; Klijn JG
    J Natl Cancer Inst; 1995 May; 87(10):751-6. PubMed ID: 7563153
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of prostate-specific antigen (PSA) correlates with poor response to tamoxifen therapy in recurrent breast cancer.
    Foekens JA; Diamandis EP; Yu H; Look MP; Meijer-van Gelder ME; van Putten WL; Klijn JG
    Br J Cancer; 1999 Feb; 79(5-6):888-94. PubMed ID: 10070886
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasminogen activator inhibitor-1 and prognosis in primary breast cancer.
    Foekens JA; Schmitt M; van Putten WL; Peters HA; Kramer MD; Jänicke F; Klijn JG
    J Clin Oncol; 1994 Aug; 12(8):1648-58. PubMed ID: 8040677
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 90K (MAC-2 BP) gene expression in breast cancer and evidence for the production of 90K by peripheral-blood mononuclear cells.
    Fusco O; Querzoli P; Nenci I; Natoli C; Brakebush C; Ullrich A; Iacobelli S
    Int J Cancer; 1998 Feb; 79(1):23-6. PubMed ID: 9495353
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Urokinase-type plasminogen activator system in breast cancer: association with tamoxifen therapy in recurrent disease.
    Meijer-van Gelder ME; Look MP; Peters HA; Schmitt M; Brünner N; Harbeck N; Klijn JG; Foekens JA
    Cancer Res; 2004 Jul; 64(13):4563-8. PubMed ID: 15231667
    [TBL] [Abstract][Full Text] [Related]  

  • 7. p53 protein accumulation predicts poor response to tamoxifen therapy of patients with recurrent breast cancer.
    Berns EM; Klijn JG; van Putten WL; de Witte HH; Look MP; Meijer-van Gelder ME; Willman K; Portengen H; Benraad TJ; Foekens JA
    J Clin Oncol; 1998 Jan; 16(1):121-7. PubMed ID: 9440732
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationship of PS2 with response to tamoxifen therapy in patients with recurrent breast cancer.
    Foekens JA; Portengen H; Look MP; van Putten WL; Thirion B; Bontenbal M; Klijn JG
    Br J Cancer; 1994 Dec; 70(6):1217-23. PubMed ID: 7981080
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The secreted tumor-associated antigen 90K is a potent immune stimulator.
    Ullrich A; Sures I; D'Egidio M; Jallal B; Powell TJ; Herbst R; Dreps A; Azam M; Rubinstein M; Natoli C
    J Biol Chem; 1994 Jul; 269(28):18401-7. PubMed ID: 8034587
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bcar1/p130Cas protein and primary breast cancer: prognosis and response to tamoxifen treatment.
    van der Flier S; Brinkman A; Look MP; Kok EM; Meijer-van Gelder ME; Klijn JG; Dorssers LC; Foekens JA
    J Natl Cancer Inst; 2000 Jan; 92(2):120-7. PubMed ID: 10639513
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasminogen activator inhibitor-2: prognostic relevance in 1012 patients with primary breast cancer.
    Foekens JA; Buessecker F; Peters HA; Krainick U; van Putten WL; Look MP; Klijn JG; Kramer MD
    Cancer Res; 1995 Apr; 55(7):1423-7. PubMed ID: 7882345
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic significance of the receptor for urokinase plasminogen activator in breast cancer.
    Grøndahl-Hansen J; Peters HA; van Putten WL; Look MP; Pappot H; Rønne E; Dano K; Klijn JG; Brünner N; Foekens JA
    Clin Cancer Res; 1995 Oct; 1(10):1079-87. PubMed ID: 9815897
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PS2 in breast cancer--alternative or complementary tool to steroid receptor status? Evaluation of 446 cases.
    Gion M; Mione R; Pappagallo GL; Gatti C; Nascimben O; Bari M; Leon AE; Vinante O; Bruscagnin G
    Br J Cancer; 1993 Aug; 68(2):374-9. PubMed ID: 8347494
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Circulating immunostimulatory protein 90K and soluble interleukin-2-receptor in human ovarian cancer.
    Zeimet AG; Natoli C; Herold M; Fuchs D; Windbichler G; Daxenbichler G; Iacobelli S; Dapunt O; Marth C
    Int J Cancer; 1996 Sep; 68(1):34-8. PubMed ID: 8895537
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic value of a novel interferon-inducible 90K tumor antigen.
    D'Ostilio N; Natoli C; Grassadonia A; Rossi N; Di Stefano P; Amatetti C; Tinari N; Iacobelli S
    Ann N Y Acad Sci; 1996 Apr; 784():288-93. PubMed ID: 8651577
    [No Abstract]   [Full Text] [Related]  

  • 16. Progesterone binding cyst protein in hormone receptor positive breast cancer; a predictive factor for effect of adjuvant tamoxifen treatment.
    Søreide JA; Kolnes J; Skarstein A; Aas T; Kvinnsland S
    Anticancer Res; 1994; 14(5B):2105-8. PubMed ID: 7840507
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic value of a novel circulating serum 90K antigen in breast cancer.
    Iacobelli S; Sismondi P; Giai M; D'Egidio M; Tinari N; Amatetti C; Di Stefano P; Natoli C
    Br J Cancer; 1994 Jan; 69(1):172-6. PubMed ID: 8286203
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The immune stimulatory protein 90K increases major histocompatibility complex class I expression in a human breast cancer cell line.
    Natoli C; Iacobelli S; Kohn L
    Biochem Biophys Res Commun; 1996 Aug; 225(2):617-20. PubMed ID: 8753808
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic value of PS2 and cathepsin D in 710 human primary breast tumors: multivariate analysis.
    Foekens JA; van Putten WL; Portengen H; de Koning HY; Thirion B; Alexieva-Figusch J; Klijn JG
    J Clin Oncol; 1993 May; 11(5):899-908. PubMed ID: 8487052
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High tumor levels of vascular endothelial growth factor predict poor response to systemic therapy in advanced breast cancer.
    Foekens JA; Peters HA; Grebenchtchikov N; Look MP; Meijer-van Gelder ME; Geurts-Moespot A; van der Kwast TH; Sweep CG; Klijn JG
    Cancer Res; 2001 Jul; 61(14):5407-14. PubMed ID: 11454684
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.